<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117946</url>
  </required_header>
  <id_info>
    <org_study_id>API/2016/67</org_study_id>
    <nct_id>NCT03117946</nct_id>
  </id_info>
  <brief_title>Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy</brief_title>
  <acronym>i-RTCT</acronym>
  <official_title>Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate modulation of anti-tumor T cell responses in cancer
      patients treated by concomitant radiochemotherapy (i-RTCT)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor antigen specific T-cell responses</measure>
    <time_frame>up to 12 months after the end of radiochemotherapy</time_frame>
    <description>tumor antigen specific T-cell responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation</measure>
    <time_frame>up to 12 months after the end of radiochemotherapy</time_frame>
    <description>monitoring of immune checkpoints, immune cell death, immune suppressive cells and T-cell polarisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>date of first progression of the disease (within 2 year after the initiation of the treatment)]</time_frame>
    <description>time interval between the date of initiation of treatment and the date of first progression (local, remote [extent of the disease by RECIST v1.1] second cancer) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>date of death from any cause (within 2 years after the initiation of the treatment)</time_frame>
    <description>time between the date of initiation of treatment and the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life related to health measured by EORTC-QLQC30</measure>
    <time_frame>from the inclusion to patient death, up to 1 year</time_frame>
    <description>Quality of life related to health measured by EORTC-QLQC30</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Biological samples</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.
Tumor tissues will be collected if available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological samples</intervention_name>
    <description>blood and tumor tissue sample</description>
    <arm_group_label>Biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed NSCLC (Non Small Cell Lung Cancer) or SCLC (small cell lung
             cancer) OR histologically confirmed Head and neck cancer

          -  Patient candidate to a first-line concomitant radiochemotherapy

          -  Written informed consent

        Exclusion Criteria:

          -  Sequential radiochemotherapy, exclusive radiotherapy, or stereotactic radiotherapy

          -  History of adjuvant radiochemotherapy for cancer treatment

          -  Patients under immunotherapy, chemotherapy or other immunosuppressive drugs
             (prednisone or prednisolone ≤ 10 mg/day is allowed)

          -  HIV, hepatitis C or B virus

          -  Patients with any medical or psychiatric condition or disease,

          -  Patients under guardianship, curatorship or under the protection of justice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier ADOTEVI, Pr</last_name>
    <phone>+33370632212</phone>
    <email>olivier.adotevi@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Depierre</last_name>
      <phone>0381218745</phone>
      <email>sdepierre@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Bernardino DE BARI, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François LECLERC</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Etienne MARTIN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>SUN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie SERVAGI VERNAT, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Stéphanie SERVAGI VERNAT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunomonitoring</keyword>
  <keyword>immune checkpoint</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

